AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21823917 — intervention group
Group type: COMPARATOR
Intervention: assessment-only conditions
Number of subjects: 50
Study 19059933 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cidofovir (0.5 mg/kg) every 2 weeks for a total of six doses
Number of subjects: 14
Study 19059933 — intervention group
Group type: COMPARATOR
Intervention: Non-cidofovir treatment (control group)
Number of subjects: 14
Study 19059933 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cidofovir
Number of subjects: 14
Study 19059933 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute rejection prior to PVAN diagnosis
Number of subjects: 14
Study 17076315 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphoric acid
Number of subjects: 0
Study 17076315 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite (NaOCl)
Number of subjects: 0
Study 17076315 — intervention group
Group type: EXPERIMENTAL
Intervention: Roth's ethylenediaminetetraacetic acid (EDTA)
Number of subjects: 0
Study 17076315 — intervention group
Group type: COMPARATOR
Intervention: Acid etching (control)
Number of subjects: 0
Study 15353407 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Number of subjects: 12
Study 15353407 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 12
Study 11250100 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 40
Study 11250100 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro erythrocyte partitioning of nitrendipine
Number of subjects: 40
Study 9612115 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb 761 (3 times 1 film-coated tablet daily for 24 weeks)
Number of subjects: 111
Study 9612115 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 times 1 film-coated tablet daily for 24 weeks)
Number of subjects: 111
Study 9612115 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb 761
Number of subjects: 111
Study 9612115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 7734800 — intervention group
Group type: EXPERIMENTAL
Intervention: PTHF1 (100% whey hydrolysate)
Number of subjects: 19
Study 7734800 — intervention group
Group type: EXPERIMENTAL
Intervention: PTHF2 (78% whey and 22% casein hydrolysed)
Number of subjects: 19
Study 7734800 — intervention group
Group type: EXPERIMENTAL
Intervention: PTHF3 (78/22 enriched with histidine)
Number of subjects: 19
Study 7734800 — intervention group
Group type: COMPARATOR
Intervention: Standard preterm formula (whey/casein: 60/40)
Number of subjects: 19
Study 2734718 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (Planphylline) 10 mg/kg/day in two doses at 8.30 a.m. and 8.30 p.m.
Number of subjects: 27
Study 2734718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 31077596 — intervention group
Group type: EXPERIMENTAL
Intervention: Cat-PAD (peptide immunotherapy)
Number of subjects: 0
Study 31077596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28049069 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week cognitive-behavioral training delivered in a group
Number of subjects: 251
Study 28049069 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week cognitive-behavioral training delivered via the internet
Number of subjects: 251
Study 28049069 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 251
Study 24885307 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback training (NFT) - SMR protocol
Number of subjects: 30
Study 24885307 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback training (NFT) - UA protocol
Number of subjects: 30
Study 24885307 — intervention group
Group type: COMPARATOR
Intervention: Sham protocol
Number of subjects: 30
Study 23218193 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (≥ 28 cDDDs)
Number of subjects: 171885
Study 23218193 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (cDDDs 28 to 90)
Number of subjects: 171885
Study 23218193 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (cDDDs 91 to 365)
Number of subjects: 171885
Study 23218193 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (cDDDs > 365)
Number of subjects: 171885
Study 23218193 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 171885
Study 21502887 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 15
Study 19333948 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg/kg/day recombinant human relaxin
Number of subjects: 0
Study 19333948 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg/kg/day recombinant human relaxin
Number of subjects: 0
Study 19333948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19333948 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxin therapy (both doses)
Number of subjects: 0
Study 16906265 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater-than-5% weight reduction
Number of subjects: 47
Study 15521115 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication-trained doctors with access to a computer-based information tool on FMS (IG I)
Number of subjects: 133
Study 15521115 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard doctors with access to the information tool on FMS (IG II)
Number of subjects: 133
Study 15521115 — intervention group
Group type: COMPARATOR
Intervention: Standard doctors with no additional information (Control Group - CG)
Number of subjects: 133
Study 11320044 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral erythromycin (12.5 mg/kg, every six hours for 14 days)
Number of subjects: 56
Study 11320044 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution (normal saline)
Number of subjects: 56
Study 9015657 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-day head-down bed rest (HDBR)
Number of subjects: 8
Study 9015657 — intervention group
Group type: COMPARATOR
Intervention: 4-day confinement (C)
Number of subjects: 8
Study 9015657 — intervention group
Group type: EXPERIMENTAL
Intervention: HUT and LBNP after HDBR and confinement
Number of subjects: 8
Study 8258511 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal subjects
Number of subjects: 70
Study 8258511 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with suspected glaucoma
Number of subjects: 70
Study 8258511 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with glaucoma
Number of subjects: 70
Study 2959308 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled histamine
Number of subjects: 12
Study 2959308 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine (H1-receptor agonist)
Number of subjects: 12
Study 2959308 — intervention group
Group type: EXPERIMENTAL
Intervention: Impromidine (H2-receptor agonist)
Number of subjects: 12
Study 2959308 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terfenadine 120 mg (pretreatment)
Number of subjects: 12
Study 2959308 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cimetidine 400 mg (pretreatment)
Number of subjects: 12
Study 30040760 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality robot‐assisted gait training (VRGT)
Number of subjects: 40
Study 30040760 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stimulation robot‐assisted gait training (ARGT)
Number of subjects: 40
Study 30040760 — intervention group
Group type: COMPARATOR
Intervention: Control group (general physical therapy)
Number of subjects: 40
Study 28199892 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 622
Study 28199892 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 622
Study 28199892 — intervention group
Group type: COMPARATOR
Intervention: Brief therapy (BT)
Number of subjects: 622
Study 28199892 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic index (PI)
Number of subjects: 622
Study 26625516 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of Lisinopril and Amlodipine
Number of subjects: 30
Study 22608892 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol
Number of subjects: 70
Study 22608892 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 70
Study 22092784 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix allograft (ADMA)
Number of subjects: 16
Study 22092784 — intervention group
Group type: COMPARATOR
Intervention: Subepithelial connective tissue graft (SCTG)
Number of subjects: 16
Study 22092784 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 16
Study 18417083 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT) after Breast-Conserving Surgery (BCS)
Number of subjects: 1222
Study 18417083 — intervention group
Group type: COMPARATOR
Intervention: No Radiation Therapy (RT) after Breast-Conserving Surgery (BCS)
Number of subjects: 1222
Study 18417083 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographic Region (West vs. Midwest)
Number of subjects: 1222
Study 18417083 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon Specialty (Surgical Oncologists vs. General Surgeons)
Number of subjects: 1222
Study 18417083 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing RT use
Number of subjects: 1222
Study 18417083 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Age, Geographic Region, Surgeon Specialty
Number of subjects: 1222
Study 16601648 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 48
Study 14765000 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower whole brain volume (WBV)
Number of subjects: 30
Study 14765000 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower Hachinski score
Number of subjects: 30
Study 14765000 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical stroke evidence at baseline
Number of subjects: 30
Study 14765000 — intervention group
Group type: COMPARATOR
Intervention: No clinical variables
Number of subjects: 30
Study 12212127 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 20 ppm nitric oxide (NO) during the early phase of reperfusion
Number of subjects: 20
Study 12212127 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nitric oxide inhalation)
Number of subjects: 20
Study 9116275 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) maintenance therapy (5 to 10 mg/kg/d) after 32P treatment
Number of subjects: 461
Study 9116275 — intervention group
Group type: COMPARATOR
Intervention: 32P treatment alone
Number of subjects: 461
Study 9116275 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) maintenance therapy
Number of subjects: 461
Study 9116275 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) maintenance therapy in severe cases with rapid recurrence
Number of subjects: 461
Study 7960627 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric acquisitions with intravenous gadolinium
Number of subjects: 14
Study 7960627 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dimensional interleaved gradient-recalled-echo pulse sequences with intravenous gadolinium
Number of subjects: 14
Study 7960627 — intervention group
Group type: EXPERIMENTAL
Intervention: Phased-array coils
Number of subjects: 14
Study 7960627 — intervention group
Group type: COMPARATOR
Intervention: Traditional time-of-flight techniques
Number of subjects: 14
Study 2884811 — intervention group
Group type: EXPERIMENTAL
Intervention: Dixyrazine (50 mg/day)
Number of subjects: 63
Study 2884811 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg/day)
Number of subjects: 63
Study 2884811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 31715274 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid responders (≥80% decrease in level of AST after 8 weeks of treatment with predniso(lo)ne)
Number of subjects: 740
Study 31715274 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid responders
Number of subjects: 740
Study 31715274 — intervention group
Group type: COMPARATOR
Intervention: Non-rapid responders
Number of subjects: 740
Study 30601172 — intervention group
Group type: EXPERIMENTAL
Intervention: 110 μm cap
Number of subjects: 116
Study 30601172 — intervention group
Group type: COMPARATOR
Intervention: 130 μm cap
Number of subjects: 116
Study 30601172 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 116
Study 28720558 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop intervention
Number of subjects: 48
Study 28720558 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 48
Study 26669201 — intervention group
Group type: EXPERIMENTAL
Intervention: Red-hot needle therapy combined with cupping
Number of subjects: 42
Study 26669201 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture combined with cupping
Number of subjects: 42
Study 23123791 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week pragmatic exercise therapy intervention
Number of subjects: 120
Study 23123791 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 120
Study 21996239 — intervention group
Group type: EXPERIMENTAL
Intervention: Caphosol (supersaturated calcium phosphate mouth rinse)
Number of subjects: 32
Study 21996239 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Caphosol)
Number of subjects: 32
Study 19055201 — intervention group
Group type: EXPERIMENTAL
Intervention: SABA nebulizer use
Number of subjects: 2056
Study 19055201 — intervention group
Group type: EXPERIMENTAL
Intervention: SABA MDI use
Number of subjects: 2056
Study 16598620 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular DDD pacing in congestive heart failure patients (N=33)
Number of subjects: 46
Study 16598620 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular DDD pacing in bradycardia patients (N=13)
Number of subjects: 46
Study 16598620 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut-off interval of 135 ms
Number of subjects: 46
Study 14519140 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/day vitamin C
Number of subjects: 300
Study 14519140 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mg/day magnesium chelate
Number of subjects: 300
Study 14519140 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 300
Study 12651048 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous milrinone for 48 to 72 hours
Number of subjects: 949
Study 12651048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 949
Study 10536541 — intervention group
Group type: EXPERIMENTAL
Intervention: AEPIndex
Number of subjects: 20
Study 10536541 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS
Number of subjects: 20
Study 9053533 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (VCM) alone
Number of subjects: 52
Study 9053533 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (VCM) in combination with beta-lactam antibiotics
Number of subjects: 52
Study 9053533 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (VCM) alone or in combination with another drug
Number of subjects: 52
Study 9053533 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (VCM)
Number of subjects: 52
Study 9053533 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (VCM) in combination with other antibiotics
Number of subjects: 52
Study 2069371 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin (400 mg) administered orally once daily for 5 days
Number of subjects: 16
Study 2069371 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered orally once daily for 5 days
Number of subjects: 16
Study 6549638 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching-counseling program combined with exercise (early cardiac rehabilitation)
Number of subjects: 0
Study 6549638 — intervention group
Group type: COMPARATOR
Intervention: Control group (exercise only)
Number of subjects: 0
Study 3947489 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (bupivacaine)
Number of subjects: 578
Study 3947489 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (enflurane or neurolept)
Number of subjects: 578
Study 3947489 — intervention group
Group type: EXPERIMENTAL
Intervention: Both anaesthetic techniques
Number of subjects: 578
Study 29685141 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinew acupuncture
Number of subjects: 86
Study 29685141 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 86
Study 28957960 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost monotherapy
Number of subjects: 35
Study 28957960 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost/dorzolamide combination
Number of subjects: 35
Study 28957960 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide monotherapy
Number of subjects: 35
Study 26151494 — intervention group
Group type: EXPERIMENTAL
Intervention: Early insulin therapy
Number of subjects: 41
Study 26151494 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 41
Study 26151494 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary cortisol
Number of subjects: 41
Study 26151494 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cortisol
Number of subjects: 41
Study 23200843 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergence of elevated liver function tests (LFTs)
Number of subjects: 376
Study 23200843 — intervention group
Group type: COMPARATOR
Intervention: Normal liver function tests (LFTs)
Number of subjects: 376
Study 23200843 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergence of elevated LFTs
Number of subjects: 376
Study 20436517 — intervention group
Group type: EXPERIMENTAL
Intervention: r-metHuSCF (ancestim) + filgrastim (r-metHuG-CSF)
Number of subjects: 32
Study 20436517 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy + filgrastim (r-metHuG-CSF)
Number of subjects: 32
Study 20436517 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (A and B)
Number of subjects: 32
Study 20436517 — intervention group
Group type: COMPARATOR
Intervention: Arm B (Chemotherapy + filgrastim)
Number of subjects: 32
Study 18360781 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive BP lowering (MAP < 110 mmHg)
Number of subjects: 42
Study 18360781 — intervention group
Group type: COMPARATOR
Intervention: Standard BP treatment (MAP 110-130 mmHg)
Number of subjects: 42
Study 16434761 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal LMA
Number of subjects: 150
Study 16434761 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIPA
Number of subjects: 150
Study 16434761 — intervention group
Group type: COMPARATOR
Intervention: Tracheal Tube (TT)
Number of subjects: 150
Study 15349658 — intervention group
Group type: EXPERIMENTAL
Intervention: IgY toothpaste
Number of subjects: 140
Study 15349658 — intervention group
Group type: COMPARATOR
Intervention: Control toothpaste
Number of subjects: 140
Study 11139951 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdrive pacing + Rest Rate
Number of subjects: 78
Study 11139951 — intervention group
Group type: COMPARATOR
Intervention: Standard DDDR
Number of subjects: 78
Study 9316188 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 37
Study 9316188 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blockade
Number of subjects: 37
Study 9316188 — intervention group
Group type: COMPARATOR
Intervention: Sham relaxation
Number of subjects: 37
Study 8330599 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. buprenorphine 0.3 mg
Number of subjects: 60
Study 8330599 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. buprenorphine 0.3 mg (prophylactic)
Number of subjects: 60
Study 8330599 — intervention group
Group type: COMPARATOR
Intervention: i.m. saline
Number of subjects: 60
Study 3550299 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (12.5 ng/kg/min before cardiopulmonary bypass and 25 ng/kg/min during cardiopulmonary bypass)
Number of subjects: 100
Study 3550299 — intervention group
Group type: COMPARATOR
Intervention: Buffer-diluent (control group)
Number of subjects: 100
Study 29766651 — intervention group
Group type: EXPERIMENTAL
Intervention: Silane application only (SIL)
Number of subjects: 40
Study 29766651 — intervention group
Group type: EXPERIMENTAL
Intervention: Silane application followed by adhesive (SILXP‐XP Bond)
Number of subjects: 40
Study 29766651 — intervention group
Group type: EXPERIMENTAL
Intervention: Silane‐containing adhesive (SBU‐ScotchBond Universal)
Number of subjects: 40
Study 29766651 — intervention group
Group type: EXPERIMENTAL
Intervention: Silane application followed by silane‐containing adhesive (SILSBU)
Number of subjects: 40
Study 27060419 — intervention group
Group type: EXPERIMENTAL
Intervention: Short and intensive speech therapy (6 hours over 3-4 days)
Number of subjects: 5
Study 23494105 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic juice replacement (R)
Number of subjects: 46
Study 23494105 — intervention group
Group type: COMPARATOR
Intervention: Pancreatic juice non-replacement (NR)
Number of subjects: 46
Study 24299462 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated glomerular filtration rate (eGFR)
Number of subjects: 669
Study 24299462 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive left ventricular filling pattern (RF)
Number of subjects: 669
Study 20953530 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubeless PCNL with double‐J stent (Group 1)
Number of subjects: 148
Study 20953530 — intervention group
Group type: COMPARATOR
Intervention: Tubeless PCNL with external ureteral catheter (Group 2)
Number of subjects: 148
Study 18655752 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 80
Study 18655752 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 80
Study 16216530 — intervention group
Group type: EXPERIMENTAL
Intervention: ln-SHBG among HT nonusers
Number of subjects: 383
Study 16216530 — intervention group
Group type: EXPERIMENTAL
Intervention: ln-testosterone among HT nonusers
Number of subjects: 383
Study 16216530 — intervention group
Group type: EXPERIMENTAL
Intervention: ln-SHBG among HT nonusers who developed CVD
Number of subjects: 383
Study 16216530 — intervention group
Group type: EXPERIMENTAL
Intervention: ln-SHBG among HT nonusers who remained CVD-free
Number of subjects: 383
Study 16216530 — intervention group
Group type: EXPERIMENTAL
Intervention: ln-SHBG among lean women
Number of subjects: 383